LaBarre A, Strauss H C, Scheinman M M, Evans G T, Bashore T, Tiedeman J S, Wallace A G
Circulation. 1979 Feb;59(2):226-35. doi: 10.1161/01.cir.59.2.226.
The electrophysiologic effects of intravenously administered disopyramide (2 mg/kg) on three parameters of sinus node function were examined in 16 symptomatic patients with sinus node dysfunction. Based on their ECG data before study, patients were subdivided into group A (n = 8), those with sinus pauses and/or sinoatrial (SA) exit block; and group B (n = 8), those with sinus bradycardia. Disopyramide shortened spontaneous cycle length in 10 of 16 patients and lengthened it in six--markedly so (91%) in one patient. Estimated SA conduction time decreased in seven of 14 patients and increased in seven. Two patients developed second degree SA exit block after disopyramide. Maximum sinus node recovery time was prolonged by disopyramide in 11 of 16 patients and markedly so in four. For the group as a whole there was no significant difference in spontaneous cycle length, maximum sinus node recovery time or estimated SA conduction time. P-wave and QRS durations and H-V intervals were significantly lengthened by disopyramide. Marked depression of the three parameters of sinus node function occurred in three group A patients and in one group B patient who had persistent severe sinus bradycardia. These four patients also had secondary pauses after termination of rapid atrial pacing under control conditions. Disopyramide should be administered cautiously to patients with sinus node dysfunction, particularly those with sinus pauses, SA exit block or secondary pauses.
在16例有症状的窦房结功能障碍患者中,研究了静脉注射丙吡胺(2mg/kg)对窦房结功能三个参数的电生理效应。根据研究前的心电图数据,患者被分为A组(n = 8),即有窦性停搏和/或窦房(SA)传导阻滞的患者;以及B组(n = 8),即有窦性心动过缓的患者。丙吡胺使16例患者中的10例自发周期长度缩短,6例延长,其中1例显著延长(91%)。14例患者中7例的估计窦房传导时间缩短,7例延长。两名患者在使用丙吡胺后出现二度窦房传导阻滞。丙吡胺使16例患者中的11例最大窦房结恢复时间延长,4例显著延长。对于整个组而言,自发周期长度、最大窦房结恢复时间或估计窦房传导时间没有显著差异。丙吡胺使P波和QRS波时限以及H-V间期显著延长。3例A组患者和1例有持续性严重窦性心动过缓的B组患者出现了窦房结功能三个参数的显著降低。这4例患者在对照条件下快速心房起搏终止后也有继发性停搏。对于窦房结功能障碍患者,尤其是有窦性停搏、窦房传导阻滞或继发性停搏的患者,应谨慎使用丙吡胺。